logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore

prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Dr Lal Pathlabs Ltd

Dr Lal Pathlabs

Large Cap4,099 EmployeesIPO 2015
Current Price
1646.30
43.4 (2.71%)Updated
NSE :LALPATHLAB
BSE :539524
Today's Range
1581.4
1646.30
indicator
1649.5
52 Week Range
52W Low1272.60
52W High3540.00
1646.30
indicator
Downside29.37%
Upside115.03%

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
24,046.66 Cr
Market Cap
Total market value of company
P/E Ratio
45.51
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
10.90
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
40.97
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
13.39%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
28.90%
ROCE
Return on Capital Employed. >15% is good
Net Margin
19.84%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
1.42%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
13.09%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
11.30%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
24.40%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.07
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
130.31
Book Value
Net asset value per share
Dividend Yield
0.85%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
53.20%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

4 points
  • Dr Lal PathLabs shows robust profitability with a 24.3% ROE and 28.9% ROCE. A healthy 28.4% OPM highlights efficient capital utilization and strong operational performance, indicating effective management of its resources.
  • The company exhibits consistent quarterly profit growth, with the latest quarter's profit at 132 Cr, marking a significant 24.4% increase, indicating a positive growth trajectory and strong operational performance.

Weaknesses

4 points
  • The company's high Price-to-Earnings (P/E) ratio of 50.40 suggests that the stock might be overvalued compared to its earnings, potentially indicating increased risk for new investors at current levels.
  • Recent stock performance shows short-term volatility, with a -0.07% change on Oct 29, 2025, and a -1.67% change on Oct 28, 2025, indicating market uncertainty and potential price fluctuations.

Opportunities

3 points
  • The increasing demand for diagnostic services, fueled by rising health awareness and an aging population, offers a significant opportunity for Dr Lal PathLabs to expand its market and revenue.
  • Expanding into underserved Tier 2 and Tier 3 cities, coupled with adopting advanced diagnostic technologies, could unlock new customer segments and enhance market penetration for the company.

Threats

3 points
  • Intense competition from both organized and unorganized players in the diagnostic services sector could exert pressure on pricing and market share, potentially impacting Dr Lal PathLabs' profitability.
  • An evolving regulatory landscape and potential changes in healthcare policies or pricing caps by the government could negatively affect the company's operational flexibility and revenue streams.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

Recent Insider Transactions

Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
Om Prakash Manchanda
30 Apr 202530 Apr 20257.89 L
19,349
₹2,802.67SELL
Dr. Lal PathLabs Employees Welfare Trust
28 Apr 202530 Apr 20251.99 L
25,436
₹1,897.14SELL
Om Prakash Manchanda
28 Apr 202530 Apr 20258.08 L
25,000
₹1,930.05BUY
Dr. Lal PathLabs Employees Welfare Trust
06 May 202506 May 20251.83 L
15,636
₹2,136SELL
Om Prakash Manchanda
06 May 202506 May 20257.79 L
10,157
₹2,793.46SELL
Om Prakash Manchanda
06 May 202506 May 20257.94 L
15,000
₹2,174.94BUY
Reena Nakra
02 May 202506 May 20259,989
400
₹1,930.05BUY
Rahul Sharma
08 May 202508 May 202519,121
5,112
₹2,832.14SELL
Reena Nakra
06 May 202508 May 20259,289
700
₹2,810SELL
Om Prakash Manchanda
09 May 202509 May 20257.99 L
10,000
₹2,174.94BUY
Dr. Lal PathLabs Employees Welfare Trust
09 May 202509 May 20251.73 L
10,000
₹2,174.94SELL
Om Prakash Manchanda
08 May 202509 May 20257.89 L
4,500
₹2,891.83SELL
Dr. Lal PathLabs Employees Welfare Trust
13 May 202515 May 20251.73 L
861
₹679.01SELL
Nimish Jindal
13 May 202515 May 20256,175
375
₹10BUY
Reena Nakra
21 May 202522 May 20259,289
300
₹2,875SELL
Reena Nakra
13 May 202522 May 20259,589
300
₹1,930.05BUY
Nimish Jindal
26 May 202526 May 20255,625
550
₹2,867.04SELL
Dr. Lal PathLabs Employees Welfare Trust
30 May 202530 May 20251.72 L
500
₹1,930.05SELL
Dr. Lal PathLabs Employees Welfare Trust
30 May 202530 May 20253.55 L
1.84 L
₹2,281.61BUY
Dr. Lal PathLabs Employees Welfare Trust
27 May 202530 May 20251.72 L
375
₹10SELL
Nimish Jindal
30 May 202502 Jun 20256,600
500
₹1,930.05BUY
Nimish Jindal
27 May 202502 Jun 20256,100
375
₹10BUY
Dr. Lal PathLabs Employees Welfare Trust
05 Jun 202506 Jun 20253.55 L
500
₹2,174.94SELL
Nimish Jindal
05 Jun 202506 Jun 20257,000
500
₹2,174.94BUY
Nimish Jindal
03 Jun 202506 Jun 20256,500
100
₹2,830SELL
Om Prakash Manchanda
10 Jun 202510 Jun 20257.83 L
16,336
₹2,880.32SELL
PUNIT SHARMA
16 Jun 202517 Jun 2025-
186
₹2,949.15SELL
PUNIT SHARMA
12 Jun 202517 Jun 2025186
186
₹10BUY
Anupa Dixit
12 Jun 202517 Jun 20251,875
625
₹10BUY
Dr. Lal PathLabs Employees Welfare Trust
12 Jun 202517 Jun 20253.53 L
1,689
₹308.7SELL

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R41806.27+₹159.97+9.72%
R31738.17+₹91.87+5.58%
R21693.83+₹47.53+2.89%
R11670.07+₹23.77+1.44%
PIVOT1625.73-20.57-1.25%
CURRENT1646.30--
S11465.77-₹180.53-10.97%
S21533.87-₹112.43-6.83%
S31557.63-₹88.67-5.39%
S41601.97-₹44.33-2.69%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
5.54L
(15 May 2026)
-34.6% vs avg
Delivery %
56.8%
(15 May 2026)
+1.4% vs avg
Avg Volume (20D)
8.47L
(17 Apr - 15 May)
20-day average
Avg Delivery %
55.4%
(17 Apr - 15 May)
Trend ↓
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Vijaya Diagnostic Centre Ltd
10,259.24 ₹ Cr
Best Profit Growth
Thyrocare Technologies Ltd
79.90 %
Highest Dividend Yield
Thyrocare Technologies Ltd
1.66 %

Peer Comparison

Company Name
KRSNAA
Krsnaa Diagnostics Ltd
METROPOLIS
Metropolis Healthcare Ltd
SURAKSHA
Suraksha Diagnostic Ltd
THYROCARE
Thyrocare Technologies Ltd
VIJAYA
Vijaya Diagnostic Centre Ltd

About

LALPATHLAB

Dr Lal Pathlabs Ltd

Dr. Lal PathLabs Limited is a prominent player in the Indian diagnostic industry, specializing in a comprehensive range of pathological investigations. Founded in 1949 and headquartered in Gurugram, India, the company operates a network of laboratories across the country and internationally, providing a wide array of diagnostic services to both individuals and healthcare institutions. Their services cater to a broad spectrum of medical needs, contributing significantly to disease diagnosis and treatment planning.

The core business of Dr. Lal PathLabs revolves around conducting a diverse range of pathological tests. Their expertise spans several key areas of laboratory medicine, including biochemistry, hematology (the study of blood), histopathology (the examination of tissues), microbiology (the study of microorganisms), electrophoresis (separation of molecules based on size and charge), immunochemistry (the study of chemical reactions involving antibodies), immunology (the study of the immune system), virology (the study of viruses), and cytology (the study of cells). This extensive coverage ensures they can handle a wide array of diagnostic requirements.

Beyond the core diagnostic offerings, Dr. Lal PathLabs also provides radiological investigations, expanding the scope of their services to include imaging techniques. This integrated approach offers healthcare providers a more complete diagnostic picture, potentially improving patient care and treatment efficacy. The company's commitment to quality and comprehensive service delivery is a key factor in their market success.

Further demonstrating a commitment to the medical field beyond direct patient services, Dr. Lal PathLabs also engages in phlebotomist training programs. This initiative addresses the need for skilled phlebotomists, who are essential for accurate and efficient sample collection, thereby contributing to the overall quality of their diagnostic services and supporting the broader healthcare system. This diversification strengthens their position within the healthcare ecosystem.

In summary, Dr. Lal PathLabs Limited is a large-scale diagnostic services provider, offering a vast menu of laboratory investigations and contributing to both clinical practice and the training of essential medical personnel. Their established presence and diverse service portfolio highlight their significant role in the Indian and international healthcare landscape.

COMPANY FACTS - LALPATHLAB

Registered Address

12th Floor, Tower B, SAS Tower, Sector 38,, Medicity, Sector-38

Gurgaon

HARYANA

IN

Company Details

Group: Health Care Equipment & Services

Sector: Health Care

Industry: Health Care Providers & Services

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 4,099

IPO Date: 23/12/2015

MANAGEMENT - LALPATHLAB

Dr. Brig. Arvind Lal

Executive Chairman of the Board

Mr. Shankha Banerjee

Chief Executive Officer

Mr. Ved Goel

Group Chief Financial Officer and Chief Executive Officer - International Business

Mr. Jai Meena

Chief Operating Officer

Mr. Manoj Garg

Group Chief Human Resources Officer

Mr. Munender Soperna

Group Chief Information and Digital Officer

Mr. Vinay Gujral

Compliance Officer, Company Secretary

Dr. Vandana Lal

Whole-Time Director

Shri. Arun Duggal

Lead Non-Executive Independent Director

Dr. Archana Erdmann

Non-Executive Director

Mr. Rahul Sharma

Non-Executive Director

Mr. Rohit Bhasin

Non-Executive Independent Director

Investor Questions Answered

Dr Lal Pathlabs Ltd (LALPATHLAB) Stock FAQs

Get answers to the most common questions about Dr Lal Pathlabs Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Dr Lal Pathlabs Ltd (LALPATHLAB) is ₹1,646.3. Today, the stock has gained by ₹43.40 (2.71%), trading in a range of ₹1,581.4 to ₹1,649.5. The stock opened at ₹1,585.1 with a trading volume of 4,82,647 shares.
Dr Lal Pathlabs Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹24,046.66 crores, P/E ratio of 45.51, ROE of 13.39%, and ROCE of 28.90%. The dividend yield stands at 0.85%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Dr Lal Pathlabs Ltd (LALPATHLAB) is ₹3,540, while the 52-week low is ₹1,272.6. Currently trading at ₹1,646.3, the stock is 16.5% away from its 52-week low and 53.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Dr Lal Pathlabs Ltd stock at ₹1,646.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 45.51 and P/B ratio of N/A. Today's performance shows a gain of 2.71%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Dr Lal Pathlabs Ltd offers a dividend yield of 0.85%, which means for every ₹100 invested at the current price of ₹1,646.3, you can expect to receive approximately ₹0.85 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Dr Lal Pathlabs Ltd's key financial metrics include: P/E Ratio: 45.51, P/B Ratio: N/A, ROE: 13.39%, ROCE: 28.90%, Dividend Yield: 0.85%, EPS: ₹40.97, Book Value: ₹130.31, Debt-to-Equity: 0.07, and Current Ratio: N/A. The company's market cap stands at ₹24,046.66 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Dr Lal Pathlabs Ltd stock opened at ₹1,585.1 and is currently trading at ₹1,646.3, showing a gain of ₹43.40 (2.71%). The intraday high is ₹1,649.5 and low is ₹1,581.4. The trading volume stands at 4,82,647 shares, indicating moderate market participation today.
Dr Lal Pathlabs Ltd has a Price-to-Earnings (P/E) ratio of 45.51, which means investors are willing to pay ₹45.51 for every ₹1 of earnings. With an EPS of ₹40.97, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Dr Lal Pathlabs Ltd has a market capitalization of ₹24,046.66 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹1,646.3) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Dr Lal Pathlabs Ltd has a book value of ₹130.31 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,646.3, which is 1163.4% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Dr Lal Pathlabs Ltd has a Return on Equity (ROE) of 13.39% and Return on Capital Employed (ROCE) of 28.90%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These are moderate returns, suggesting decent operational efficiency. Higher percentages generally indicate better financial performance.
Dr Lal Pathlabs Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Dr Lal Pathlabs Ltd has a debt-to-equity ratio of 0.07, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Dr Lal Pathlabs Ltd has an Earnings Per Share (EPS) of ₹40.97, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,646.3 and P/E ratio of 45.51, investors are paying 45.51 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Dr Lal Pathlabs Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Dr Lal Pathlabs Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Dr Lal Pathlabs Ltd stock, consider: 1) Fundamental Analysis - Review P/E (45.51), ROE (13.39%), debt-to-equity (0.07), and growth rates. 2) Technical Analysis - Check 52-week range (₹1272.60 - ₹3540.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1646.30) with book value (₹130.31) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Dr Lal Pathlabs Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,646.3 is 16363x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Dr Lal Pathlabs Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1272.60 - ₹3540.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.07 indicates leverage. 4) Liquidity Risk - Based on trading volume of 4,82,647 shares. 5) Valuation Risk - P/E of 45.51 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Dr Lal Pathlabs Ltd operates in the industry with key metrics: P/E ratio of 45.51, ROE of 13.39%, market cap of ₹24,046.66 crores, and dividend yield of 0.85%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.07), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Dr Lal Pathlabs Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,646.3, with a 52-week range of ₹1272.60 to ₹3540.00. Based on fundamentals like P/E (45.51), ROE (13.39%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Dr Lal Pathlabs Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1646.30. 2) Fundamental Deterioration - Declining ROE (currently 13.39%), increasing debt (D/E: 0.07), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Dr Lal Pathlabs Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.85%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.